|1.||Schneider, Armin: 24 articles (06/2015 - 08/2005)|
|2.||Schäbitz, Wolf-Rüdiger: 23 articles (08/2014 - 08/2005)|
|3.||Dale, David C: 21 articles (01/2016 - 01/2002)|
|4.||Szmitkowski, Maciej: 19 articles (12/2012 - 04/2002)|
|5.||Welte, Karl: 17 articles (04/2014 - 04/2002)|
|6.||Lyman, Gary H: 17 articles (06/2013 - 04/2002)|
|7.||Calandra, Gary: 14 articles (12/2013 - 08/2006)|
|8.||Komuro, Issei: 14 articles (09/2012 - 01/2003)|
|9.||Yamazaki, Masashi: 13 articles (08/2015 - 05/2007)|
|10.||Koda, Masao: 13 articles (08/2015 - 05/2007)|
11/01/2007 - "In most patients PEG-IFN-alpha induced neutropenia improved with a once-a-week dose of G-CSF with a comparable virological outcome. "
01/01/2015 - "Severe neutropenia can be successfully treated with granulocyte colony-stimulating factor. "
05/01/2014 - "G-CSF pathway-compliant treatment was associated with a significant reduction in neutropenia ED visits/hospitalizations compared with noncompliant treatment (odds ratio [OR] = 0.34; 95% CI, 0.25 to 0.45; P < .001). "
08/01/1997 - "The duration of neutropenia and absolute neutrophil nadir counts were significantly improved by administration of G-CSF. "
01/01/1996 - "Granulocyte colony-stimulating factor is effective in reducing the otherwise observed high rate of WHO grade III/IV hematological toxicity with severe neutropenia."
08/01/1992 - "These results demonstrate that G-CSF is a potent immunomodulator that stimulates neutrophil function and also increases their recruitment to the site of infection, resulting in improved bacterial killing and host defense."
02/15/2001 - "There is evidence from animal and clinical studies that administration of granulocyte colony-stimulating factor may also be beneficial in non-neutropenic infections. "
01/01/2013 - "Our results question the use of G-CSF in a post-PBSCT setting, as it does not provide significant benefits in reducing the number of infections or shortening the duration of hospitalization."
10/01/2002 - "Documented bacterial, viral or fungal infections did not occur more often when G-CSF treatment was started on day 9. Delaying treatment with G-CSF resulted in a significant reduction in the length of treatment from 13 to 10 days (23.1% reduction). "
10/01/1998 - "The good results in terms of neutrophils increment and infection prophylaxis render G-CSF attractive for treating AIN. "
10/01/1993 - "It is now 2 years since the commercial availability of G-CSF, and thus it seems appropriate to reassess the clinical merits of this cytokine in the context of current knowledge; such an evaluation seems best founded not only on an analysis of the biology of G-CSF itself, but also on a critical assessment of whether its biologic actions translate into a cost-effective alleviation of patient suffering and improved cancer cure. "
01/01/1992 - "These preliminary findings thus suggested that G-CSF should not be effective in the treatment of neutropenic cancer patients with P. "
05/01/2012 - "Our experience indicates that the use of biosimilar G-CSF is safe and effective at reducing neutropenic complications in patients with solid tumors and may be associated with cost savings."
11/01/2012 - "Therefore, we performed a statistical combination of controlled clinical trials to investigate the efficacy of prophylactic use of G-CSF in preventing the neutropenic complications associated with SCT following HDCT in cancer patients. "
06/01/2015 - "Identification of G-CSF genes helped us further understand the mechanism by which G-CSF promotes cancer. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/2003 - "Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22)."
09/01/1997 - "Complete remission in three patients with acute myeloblastic leukemia by administration of G-CSF without antileukemic agents."
06/01/1995 - "G-CSF combined conditioning regimen seems to be effective for ANLL in complete remission (CR) probably by in vivo purging of residual leukemic cells. "
09/17/2009 - "In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation."
07/01/2008 - "G-CSF-induced remission in two cases of acute myeloid leukemia."
11/07/2006 - "G-CSF treatment significantly improved left ventricle function and reduced infarct size in rats with acute myocardial infarction. "
01/01/2011 - "A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'."
12/01/2007 - "The purpose of our perspective randomized trial is to evaluate the efficacy of G-CSF administration, assessed by improvement of LV ejection fraction by cardiac magnetic resonance imaging (MRI), in patients with acute anterior myocardial infarction undergoing primary percutaneous coronary intervention (PCI) and with evidence of LV dysfunction. "
10/01/2007 - "Several clinical trials have been performed to study the efficacy of G-CSF therapy in patients with acute myocardial infarction but the results remain controversial because the protocols followed varied between the trials."
10/13/2008 - "Safety and efficacy of granulocyte colony-stimulating factor for patients with recent myocardial infarction: a meta-analysis."
|1.||Granulocyte Colony-Stimulating Factor (G-CSF)
|2.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|5.||Anti-Bacterial Agents (Antibiotics)
|8.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Transplantation (Transplant Recipients)
|3.||Hematopoietic Stem Cell Mobilization
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)